Strengths

Negative cash conversion cycle supports working-capital efficiency versus most pharmacy peers, partially offsetting weak profitability and balance-sheet strain.

Scale in U.S. retail pharmacy and pharmacy services preserves purchasing leverage and network relevance versus smaller peers, even as industry margins remain thin.

Diversified cash-generating healthcare distribution and retail operations provide some resilience versus pure-play retailers, helping absorb demand volatility across channels.

Weaknesses

Negative TTM ROIC indicates capital is still destroying value, leaving Walgreens structurally behind stronger peers that earn positive returns on invested capital.

Current and quick ratios below 1.0 signal tight liquidity versus better-capitalized peers, increasing refinancing dependence and reducing operating flexibility.

High leverage and elevated debt-to-equity constrain strategic optionality versus peers, because more cash flow must service debt rather than fund reinvestment.

Persistently weak margin profile versus pharmacy peers reflects intense reimbursement pressure and limited pricing power, which keeps earnings quality structurally fragile.

Opportunities

Store rationalization and footprint optimization could improve productivity versus larger peers, because closing underperforming locations can lift average economics and capital efficiency.

Greater mix shift toward higher-margin healthcare services and specialty pharmacy could narrow the profitability gap versus traditional retail peers over time.

Working-capital discipline can remain a relative advantage if inventory and payables management stay tight, supporting cash generation better than less efficient peers.

Threats

Intense reimbursement pressure from payers and pharmacy benefit managers threatens margins versus peers, because industry pricing power remains structurally weak.

Ongoing consumer migration to lower-cost channels and mail-order fulfillment can erode front-end traffic versus omnichannel peers, reducing store productivity.

High leverage leaves Walgreens more exposed than peers to refinancing risk and interest-cost pressure, especially if operating performance stays weak.

Competitive intensity from larger pharmacy chains and integrated healthcare players can compress share and economics versus peers, limiting any durable recovery in positioning.

Overall Score

Walgreens Boots Alliance remains structurally weak versus peers because leverage, liquidity pressure, and poor capital returns outweigh its scale and working-capital advantages.